IP Library Granted Patent US 7,795,444
Granted Patent B2
US 7,795,444 · App. 11/821,846 · Granted Sep 14, 2010

Human protein tyrosine phosphatase inhibitors and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,444
App. No.
11/821,846
Granted
Sep 14, 2010
Kind
B2
Abstract

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

Claims (241)

1. A compound having the formula:

wherein R is a substituted or unsubstituted thiazolyl unit having the formula:

R 2 and R 3 are each independently chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted phenyl;

iv) substituted or unsubstituted heteroaryl; or

R 2 and R 3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms;

said substitutions are independently chosen from one or more C 1 -C 6 linear, C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 1 -C 4 linear or C 3 -C 4 branched alkyl;

R 4 is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted phenyl; or

iv) substituted or unsubstituted heteroaryl;

said substitutions are independently chosen from one or more C 1 -C 6 linear C 3 -C 6 branched, or C 1 -C 6 cyclic alkyl, —N(R 11 ) 2 , —OR 11 , halogen, hydroxyl, or cyano units; each R 11 is independently hydrogen, C 1 -C 4 linear or C 3 -C 4 branched alkyl;

Z is a unit having the formula:

-(L) n -R 1

R 1 is chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted aryl;

iv) substituted or unsubstituted heterocyclic rings; or

v) substituted or unsubstituted heteroaryl rings;

said substitutions are independently chosen from one or more halogen, C 1 -C 6 linear, C 6 branched, or C 3 -C 6 cyclic alkyl, —OR 11 , —CN, —N(R 11 ) 2 , —CO 2 R 11 , —C(O)N(R 11 ) 2 , —NR 11 C(O)R 11 , —NO 2 , —SO 2 R 11 , phenyl, benzyl; when R 11 is substituted by phenyl or benzyl, said phenyl or benzyl can be substituted by halogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, —CO 2 R 11 and —NHCOR 16 ; each R 11 is independently hydrogen; substituted or unsubstituted C 1 -C 4 linear, branched, cyclic alkyl, alkenyl, or alkenyl; substituted or unsubstituted phenyl or benzyl; or two R 11 units can be taken together to form a ring comprising from 3-7 atoms; each R 16 is independently hydrogen, methyl, or ethyl;

L is a linking unit chosen from:

i) —C(O)NH[C(R 5a R 5b )] w —;

ii) —C(O)[C(R 6a R 6b )] x —;

iii) —C(O)[C(R 7a R 7b ] y C(O)—;

iv) —SO 2 [C(R 8a R 8b )] z —;

R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8a , and R 8b are each independently:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 4 linear or C 3 -C 4 branched alkyl;

iii) substituted or unsubstituted aryl;

iv) substituted or unsubstituted heterocyclic rings; or

v) substituted or unsubstituted heteroaryl rings;

the index n is 0 or 1; the indices w and z are each independently from 0 to 4 and the indices x and y are each independently from 1 to 4;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein R has the formula:

3. A compound according to claim 2 , wherein R 2 and R 3 are each hydrogen or substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl.

4. A compound according to claim 3 , wherein R 2 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tent-butyl; and R 3 is hydrogen.

5. A compound according to claim 4 , wherein R 2 is methyl or ethyl.

6. A compound according to claim 2 , wherein R 2 is substituted or unsubstituted phenyl and R 3 is hydrogen.

7. A compound according to claim 2 , wherein R 2 is substituted or unsubstituted heteroaryl and R 3 is hydrogen.

8. A compound according to claim 7 , wherein R 2 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

9. A compound according to claim 8 , wherein R 2 is thiophene-2-yl or thiophene-3-yl.

10. A compound according to claim 1 , wherein R has the formula:

11. A compound according to claim 10 , wherein R 4 is hydrogen or substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl.

12. A compound according to claim 11 , wherein R 4 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tent-butyl; and R 3 is hydrogen.

13. A compound according to claim 12 , wherein R 4 is methyl or ethyl.

14. A compound according to claim 10 , wherein R 4 is substituted or unsubstituted phenyl and R 3 is hydrogen.

15. A compound according to claim 10 , wherein R 4 is substituted or unsubstituted heteroaryl.

16. A compound according to claim 15 , wherein R 4 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

17. A compound according to claim 16 , wherein R 4 is thiophene-2-yl or thiophene-3-yl.

18. A compound according to claim 1 , wherein L has the formula:

—C(O)[C(R 6a R 6b )] x —

R 6a is hydrogen, substituted or unsubstituted phenyl, and substituted or unsubstituted heteroaryl; the index x is 1 or 2.

19. A compound according to claim 18 , wherein R 1 is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl.

20. A compound according to claim 19 , wherein R has the formula:

21. A compound according to claim 20 , wherein R 2 is methyl or ethyl, R 3 is hydrogen, and L has the formula —C(O)CH 2 —.

22. A compound according to claim 20 , wherein R 2 is methyl or ethyl, R 3 is hydrogen, and L has the formula —C(O)CH 2 CH 2 —.

23. A compound according to claim 19 , wherein R has the formula:

24. A compound according to claim 23 , wherein R 4 is methyl, ethyl, phenyl, thiophene-2-yl, thiazol-2-yl, oxazol-2-yl, and isoxazol-3-yl; and L has the formula —C(O)CH 2 —.

25. A compound according to claim 23 , wherein R 4 is methyl, ethyl, phenyl, thiophene-2-yl, thiazol-2-yl, oxazol-2-yl, and isoxazol-3-yl; and L has the formula —C(O)CH 2 CH 2 —.

26. A compound according to claim 1 , wherein R 1 is a substituted or unsubstituted heteroaryl unit, said substitutions chosen from:

i) C 1 -C 6 linear, branched, and cyclic alkyl;

ii) substituted or unsubstituted phenyl and benzyl;

iii) substituted of unsubstituted heteroaryl;

iv) —C(O)R 9 ; or

v) —NHC(O)R 9 ;

R 9 is C 1 -C 6 linear and C 3 -C 6 branched alkyl; C 1 -C 6 linear and C 3 -C 6 branched alkoxy; or —NHCH 2 C(O)R 10 ; R 10 is chosen from hydrogen, methyl, ethyl, and tert-butyl.

27. A compound according to claim 26 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an alkyl unit chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl.

28. A compound according to claim 26 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by substituted or unsubstituted phenyl and benzyl, said phenyl and benzyl substitutions are chosen from one or more:

i) halogen;

ii) C 1 -C 3 alkyl;

iii) C 1 -C 3 alkoxy;

iv) —CO 2 R 11 ; or

v) —NHCOR 12 ;

wherein R 11 and R 12 are each independently hydrogen, methyl, or ethyl.

29. A compound according to claim 26 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by a carboxy unit having the formula —C(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, and ethoxy.

30. A compound according to claim 26 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an amide unit having the formula —NHC(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, ethoxy, tent-butyl, and tert-butoxy.

31. A compound according to claim 1 , having the formula:

wherein R 2 is methyl or ethyl, R 3 is hydrogen, R 6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl.

32. A compound according to claim 1 , having the formula:

wherein R 2 is methyl or ethyl, R 3 is hydrogen, R 6a is chosen from 3-methyl-1,2,4-oxadiazol-5-yl, thiophene-2-yl, thiophene-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, and isoxazol-3-yl.

33. A compound according to claim 1 , having the formula:

wherein R 4 is methyl, ethyl, phenyl, or thiophene-2-yl, R 6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl.

34. A compound according to claim 1 , having the formula:

wherein R 4 is methyl, ethyl, phenyl, or thiophene-2-yl, R 6a is chosen from 3-methyl-1,2,4-oxadiazol-5-yl, thiophene-2-yl, thiophene-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, and isoxazol-3-yl.

35. A compound according to claim 1 , having the formula:

wherein R 2 is chosen from methyl, ethyl, phenyl, and thiophene-2-yl, R 3 is hydrogen or methyl; R 1 is chosen from phenyl, thiophene-2-yl, thiophene-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, and isoxazol-3-yl.

36. A compound according to claim 1 , having the formula:

wherein R 2 and R 3 are each independently hydrogen, methyl or ethyl; R 1 is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl.

37. A compound having the formula:

wherein L is —SO 2 [CH 2 ] z —; R 4 is C 1 -C 4 linear or C 3 -C 4 branched alkyl, or thiophene-2-yl; R 1 is substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched or C 3 -C 6 cyclic alkyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl rings, the index z is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

38. A compound according to claim 37 , wherein R 1 is methyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, phenyl, 4-fluorophenyl, 4-acetamidophenyl, (4-methyl-carboxyphenyl)methyl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1-methyl-1H-imidazol-4-yl, and (2-methylthiazol-4-yl)methyl.

39. A compound having the formula:

wherein R 1 is a substituted or unsubstituted heteroaryl unit chosen from:

i) 1,2,3,4-tetrazol-1-yl and 1,2,3,4-tetrazol-5-yl having the respective formulae:

ii) [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, and [1,2,4]triazol-5-yl having the respective formulae:

iii) imidazol-2-yl and imidazol-4-yl having the respective formulae:

iv) pyrrol-2-yl and pyrrol-3-yl having the respective formulae:

v) oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl having the respective formulae:

vi) isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl having the respective formulae:

vii) [1,2,4]oxadiazol-3-yl and [1,2,4]oxadiazol-5-yl having the respective formulae:

viii) [1,3,4]oxadiazol-2-yl having the formula:

ix) furan-2-yl and furan-3-yl having the respective formulae:

x) thiophene-2-yl and thiophene-3-yl having the respective formulae:

xi) isothiazol-3-yl, isothiazol-4-yl and isothiazol-5-yl having the respective formulae:

xii) thiazol-2-yl, thiazol-4-yl and thiazol-5-yl having the respective formulae:

xiii) [1,2,4]thiadiazol-3-yl and [1,2,4]thiadiazol-5-yl having the respective formulae:

said heteroaryl unit substitutions chosen from:

i) C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkyl;

ii) substituted or unsubstituted phenyl and benzyl;

iii) substituted of unsubstituted heteroaryl;

iv) —C(O)R 9 ; or

v) —NHC(O)R 9 ;

R 9 is C 1 -C 6 linear and C 3 -C 6 branched alkyl; C 1 -C 6 linear and C 3 -C 6 branched alkoxy; or —NHCH 2 C(O)R 10 ; R 10 is chosen from hydrogen, methyl, ethyl, and tert-butyl;

R 4 is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, C 3 -C 6 branched, or C 3 -C 6 cyclic alkyl;

iii) substituted or unsubstituted phenyl; or

iv) substituted or unsubstituted heteroaryl;

or a pharmaceutically acceptable salt thereof.

40. A compound according to claim 39 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an alkyl unit chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl.

41. A compound according to claim 39 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by substituted or unsubstituted phenyl and benzyl, said phenyl and benzyl substitutions are chosen from one or more:

i) halogen;

ii) C 1 -C 3 alkyl;

iii) C 1 -C 3 alkoxy;

iv) —CO 2 R 11 ; or

v) —NHCOR 12 ;

wherein R 11 and R 12 are each independently hydrogen, methyl, or ethyl.

42. A compound according to claim 39 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by a carboxy unit having the formula —C(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, and ethoxy.

43. A compound according to claim 39 , wherein said R 1 substituted or unsubstituted heteroaryl unit is substituted by an amide unit having the formula —NHC(O)R 9 ; R 9 is chosen from methyl, methoxy, ethyl, ethoxy, tent-butyl, and tert-butoxy.

44. A compound according to claim 39 , wherein R 1 is chosen from 4-(methoxy-carbonyl)thiazol-5-yl, 4-[(2-methoxy-2-oxoethyl)carbamoyl]thiazol-5-yl, 5-[1-N-(2-methoxy-2-oxoethyl)-1-H-indol-3-yl]oxazol-2-yl, 5-(2-methoxyphenyl)oxazol-2-yl, 5-[(S)-1-(tert-butoxycarbonyl)-2-phenylethyl]oxazol-2-yl, 5-[4-(methyl-carboxy)phenyl]oxazol-2-yl, 5-(3-methoxybenzyl)oxazol-2-yl, 5-(4-phenyl)-oxazol-2-yl, 5-(2-methoxyphenyl)thiazol-2-yl, 5-(3-methoxyphenyl)thiazol-2-yl, 5-(4-fluorophenyl)thiazol-2-yl, 5-(2,4-difluorophenyl)thiazol-2-yl, 5-(3-methoxy-benzyl)thiazol-2-yl, 4-(3-methoxyphenyl)thiazol-2-yl, and 4-(4-fluorophenyl)-thiazol-2-yl.

45. A compound according to claim 39 , wherein R 4 is chosen from methyl, ethyl, cyclopropyl, phenyl, and thiophene-2-yl.

46. A compound chosen from:

(S)-{-4-[2-(S)-(4-Ethylthiazol-2-yl)-2-(2-phenylacetylamido)ethyl]phenyl}sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(2-fluorophenyl)acetamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-fluorophenyl)acetamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(2-(2,3-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(2-(3,4-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(2-(2-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(2-(3-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-hydroxyphenyl)acetamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(2-methoxyphenyl)acetamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-methoxyphenyl)acetamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-phenylpropanamido)ethyl)phenylsulfamic acid;

(S)-4-(2-(2-(3,4-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)-phenylsulfamic acid;

(S)-4-(2-(2-(2,3-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)-phenylsulfamic acid;

(S)-4-(2-(3-(3-Chlorophenyl)propanamido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(2-methoxyphenyl)propanamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(3-methoxyphenyl)propanamido)ethyl)phenyl-sulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(4-methoxyphenyl)propanamido)ethyl)phenyl-sulfamic acid;

(S)-4-{2-[2-(4-Ethyl-2,3-dioxopiperazin-1-yl)acetamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-acetamido]ethyl}phenylsulfamic acid; and

(S)-4-[2-(Benzo[d][1,3]dioxole-5-carboxamido)-2-(4-ethylthiazol-2-yl)ethyl]-phenylsulfamic acid;

or a pharmaceutically salt thereof.

47. A compound chosen from:

4-((S)-2-(2-(2-Chlorophenyl)acetamido)-2-(2-(thiophen-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(2-(3-Methoxyphenyl)acetamido)-2-(2-(thiophen-yl)thiazol-4-yl)ethyl)-phenylsulfamic acid;

4-{(S)-2-(3-Phenylpropanamido)-2-[2-(thiophen-yl)thiazol-4-yl]ethyl}phenyl-sulfamic acid;

4-{(S)-2-(3-(3-Chlorophenyl)propanamido)-2-[2-(thiophen-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

4-{(S)-2-[2-(3-Fluorophenyl)acetamido]-2-[2 thiophen-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

(S)-4-{2-[2-(2,5-Dimethylthiazol-4-yl)acetamido]-2-(4 ethylthiazol-2-yl)ethyl}-phenylsulfamic acid;

(S)-4-{2-[2-(2,4-Dimethylthiazol-5-yl)acetamido]-2-(4 methylthiazol-2-ylethyl}phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[3-(thiazol-2-yl)propanamido]ethyl}phenyl-sulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(4-ethylthiazol-2-yl)acetamido]ethyl}phenylsulfamic acid;

(S)-4-{2-[2-(3-Methyl-1,2,4-oxadiazol-5-yl)acetamido]-2-(2-phenylthiazol-4-yl)ethyl}phenylsulfamic acid; and

4-{(S)-2-[2-(4-Ethyl-2,3-dioxopiperazin-1-yl)acetamido]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

or a pharmaceutically acceptable salt thereof.

48. A compound chosen from:

(S)-4-(2-(2,3-Diphenylpropanamido)-2-(4-ethylthiazol-2-yl)ethyl)phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(2-methoxyphenyl)-3-phenylpropanamido]-ethyl)phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(2-fluorophenyl)-3-phenylpropanamido]-ethyl}phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-fluorophenyl)-3-phenylpropanamido]-ethyl}phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-methoxyphenyl)-3-phenylpropanamido]-ethyl}phenylsulfamic acid;

4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phenylpropanamido]ethyl}phenylsulfamic acid;

(S)-4-[2-(4-Ethylthiazol-2-yl)-2-(4-oxo-4-phenylbutanamido)-ethyl]phenylsulfamic acid;

(S)-4-(2-(4-Ethylthiazol-2-yl)-2-(5-methyl-4-oxohexanamido)ethyl)phenyl-sulfamic acid;

(S)-4-{2-[4-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-4-oxobutanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid;

(S)-4-{2-[4-(2,3-Dimethoxyphenyl)-4-oxobutanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid;

(S)-4-{2-(4-Ethylthiazol-2-yl)-2-[4-oxo-4-(pyridin-2-yl)butanamido]ethyl}-phenylsulfamic acid;

(S)-4-{2-[4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-oxobutanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid;

(S)-4-[2-(4-tert-Butoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phenyl-sulfamic acid;

(S)-4-[2-(4-Ethoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phenylsulfamic acid;

(S)-4-(2-(3-Benzylureido)-2-(4-ethylthiazol-2-yl)ethyl)phenyl-sulfamic acid;

4-{[(S)-2-(2-Ethylthiazol-4-yl)-2-(3-(R)-1methoxy-1-oxo-3-phenylpropan-2-yl)ureido]ethyl}phenylsulfamic acid; and

4-{(S)-2-(3-Benzylureido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenyl-sulfamic acid;

or a pharmaceutically acceptable salt thereof.

49. A compound chosen from:

{4-(S)-[2-Phenylmethanesulfonylamino-2-(2-thiophen-2-ylthiazol-4-yl)ethyl]phenyl}sulfamic acid;

4-{(S)-2-[(2-Methylthiazol-4-yl)methylsulfonamido]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

{4-(S)-[2-Phenylmethanesulfonylamino-2-(2-ethylthiazol-4-yl)ethyl]phenyl}-sulfamic acid;

(S)-(4-(2-(2-ethylthiazol-4-yl)-2-((3-methoxyphenyl)methylsulfonamido)-ethyl)phenyl)sulfamic acid;

(S)-4-{[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylsulfamoyl]methyl}-benzoic acid methyl ester;

(S)-4-[2-(2-Ethylthiazol-4-yl)-2-(1-methyl-1H-imidazol-4-sulfonamido)ethyl]-phenylsulfamic acid;

4-{(S)-2-[2-(Thiophen-2-yl)thiazol-4-yl]-2-(2,2,2-trifluoroethylsulfonamido)-ethyl}phenylsulfamic acid;

(4-(2-(phenylmethylsulfonamido)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenyl)sulfamic acid;

(4-(2-(phenylmethylsulfonamido)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenyl)sulfamic acid;

(S)-(4-{2-(3-Phenylpropylsulfonamido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenyl)sulfamic acid;

(S)-{4-[2-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonylamino)-2-(2-thiophen-2-ylthiazol-4-yl)ethyl]phenyl}sulfamic acid; and

4-{(S)-2-(4-Acetamidophenylsulfonamido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

or a pharmaceutically acceptable salt thereof.

50. A compound chosen from:

4-{(S)-2-(2-cyclopropylthiazol-4-yl)-2-[4-(3-methoxyphenyl)-thiazol-2-ylamino]ethyl}phenylsulfamic acid;

(S)-4-(2-(4-((2-Methoxy-2-oxoethyl)carbamoyl)thiazole-5-ylamino)-2-(2-ethylthiazole-4-yl)ethyl)phenylsulfamic acid;

(S)-(4-(2-((3-((2-methoxy-2-oxoethyl)carbamoyl)-1H-indol-2-yl)amino)-2-(2-methylthiazol-4-yl)ethyl)phenyl)sulfamic acid;

4-((S)-2-(5-(2-Methoxyphenyl)oxazol-2-ylamino)-2-(2-methylthiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(5-((S)-1-(tert-Butoxycarbonyl)-2-phenylethyl)oxazole-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl)phenylsulfamic acid;

(S)-4-(2-(5-(4-Methoxycarbonyl)phenyl)oxazole-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl)phenylsulfamic acid;

(S)-4-(2-(5-(3-Methoxybenzyl)oxazole-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl)phenylsulfamic acid;

(S)-4-(2-(2-Methylthiazole-4-yl)-2-(5-phenyloxazole-2-ylamino)ethyl)phenyl-sulfamic acid;

4-((S)-2-(2-Cyclopropylthiazol-4-yl)-2-(4-(3-methoxyphenyl)thiazol-2-ylamino)ethyl)phenylsulfamic acid;

(S)-4-(2-(2-cyclopropylthiazol-4-yl)-2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)phenylsulfamic acid;

4-((S)-2-(2-cyclopropylthiazol-4-yl)-2-(4-(2-methoxyphenyl)thiazol-2-ylamino)ethyl)phenylsulfamic acid;

4-((S)-2-(2-cyclopropylthiazol-4-yl)-2-(4-(2,4-difluorophenyl)thiazol-2-ylamino)ethyl)phenylsulfamic acid;

(S)-4-(2-(4-(3-methoxybenzyl)thiazol-2-ylamino)-2-(2-cyclopropylthiazol-4-yl)ethyl)phenylsulfamic acid;

(S)-{5-[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylamino]-2-methyl-2H-[1,2,4]triazole-3-yl}carbamic acid methyl ester;

(S)-[4-(2-{[4-(3-Methoxyphenyl)thiazol-2-yl]amino}-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl)phenyl]sulfamic acid;

4-{(S)-2-[5-(3-Methoxyphenyl)oxazole-2-ylamino]-2-(2-phenylthiazole-4-yl)ethyl}phenylsulfamic acid;

4-{(S)-2-[4-(2,4-Difluorophenyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

(S)-4-{2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)ethyl}phenylsulfamic acid;

(S)-4-{2-[4-(2-Ethoxy-2-oxoethyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)ethyl}phenylsulfamic acid;

(S)-4-{2-[4-(4-Acetamidophenyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)ethyl}phenylsulfamic acid;

(S)-4-[2-(4-Phenylthiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]phenyl-sulfamic acid;

(S)-4-{2-[4-(4-(Methoxycarbonyl)phenyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)ethyl}phenylsulfamic acid;

4-{(S)-2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid;

(S)-4-[2-(4-(Methoxycarbonyl)thiazol-5-ylamino)-2-(2-phenylthiazole-4-yl)ethyl]phenylsulfamic acid;

(S)-4-[2-(5-Phenyloxazole-2-ylamino)]-2-(2-phenylthiazole-4-yl)phenylsulfamic acid;

(S)-4-{2-[5-(4-Acetamidophenyl)oxazole-2-ylamino]-2-(2-phenylthiazole-4-yl)ethyl}phenylsufamic acid;

4-((S)-2-(5-(2,4-Difluorophenyl)oxazole-2-ylamino)-2-(2-phenylthiazole-4-yl)ethyl)phenylsulfamic acid;

4-{(S)-2-[5-(3-Methoxyphenyl)oxazol-2-ylamino]-2-[(2-thiophen-2-yl)thiazole-4-yl]ethyl}phenylsulfamic acid;

(S)-4-[2-(4,6-Dimethylpyrimidene-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl]phenylsulfamic acid; and

(S)-4-[2-(4-Hydroxy-6-methylpyrimidin-2-ylamino)-2-(2-methylthiazole-4-yl)ethyl]phenylsulfamic acid;

or a pharmaceutically acceptable salt thereof.

51. Composition comprising:

A) one or more compounds according to claim 1 , or a pharmaceutically acceptable salt thereof; and

B) one or more excipients or carriers.

52. A compound according to claim 1 , wherein the compounds are salts comprising anions chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

53. A compound according to claim 1 , wherein the compounds are salts comprising cations chosen from sodium, lithium, potassium, calcium, magnesium, and bismuth.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: AERPIO THERAPEUTICS LLC
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052432/0789 →
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049922/0273 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2012
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 027796/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS INC.
Reel/Frame 027445/0100 →
PATENT RELEASE Recorded Dec 23, 2011
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 027443/0164 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
SECURITY AGREEMENT Recorded Nov 2, 2009
From: WARNER CHILCOTT COMPANY, LLC
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023456/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: AMARASINGHE, KANDE K. D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW; MAIER, MATTHEW B.
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 022254/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2007
From: GRAY, JEFFREY LYLE
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 020202/0250 →